Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.13 USD | +3.68% | -7.91% | +65.52% |
May. 14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
May. 13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Evolution of the average Target Price on Inovio Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Inovio Pharmaceuticals, Inc.
Stephens Inc. | |
Oppenheimer | |
RBC Capital Markets | |
Maxim | |
Loop Capital | |
BofA Securities | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- INO Stock
- Consensus Inovio Pharmaceuticals, Inc.